-
Mashup Score: 0phase 2 study of Interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract - 1 year(s) ago
Key Points. Use of the rhIL-22 dimer F-652 with systemic steroids appeared safe and associated with a high response rate in newly diagnosed GI GVHD.Patients res
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 3
In the latest article from SIDP, here is a look at the use of various intravenous (IV) antimicrobial therapies to address infections in these patients.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 3
Official website for the University of Miami Leonard M. Miller School of Medicine
Source: med.miami.eduCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0Vancomycin AUC Implementation in Resource-Limited Settings and its Associated Difficulties - 3 year(s) ago
The latest article from SIDP illustrates the challenges of area under the curve (AUC) implementation and offers insights for strategies and resources to overcome them.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 4Epigenetic Therapy for Epithelioid Sarcoma - 4 year(s) ago
Tazemetostat is the first epigenetic therapy to gain FDA approval in a solid tumor. This lysine methyltransferase inhibitor targets EZH2, the enzymatic subunit of the PRC2 transcriptional silencing complex. Tumors with mutations in subunits of the SWI/SNF chromatin remodeling complex, inclusive of most epithelioid sarcomas, are sensitive to EZH2 inhibition.
Source: CellCategories: General Medicine Journals and SocietiesTweet
-
Mashup Score: 1A New Rapid-Acting Antidepressant - 4 year(s) ago
The discovery of the strikingly rapid and robust antidepressant effects of r/s-ketamine for the treatment of antidepressant-resistant symptoms of depression has led to new insights into the biology of antidepressants and the FDA approval of its s-isomer, Esketamine (Spravato), the first mechanistically new treatment for depression in over 60 years. To view this Bench to Bedside, open or download…
Source: CellCategories: General Medicine Journals and SocietiesTweet
-
Mashup Score: 3A Vaccine against Ebola Virus - 4 year(s) ago
Ervebo is the first licensed vaccine for prevention of Ebola virus disease. The vaccine, originally developed by the Public Health Agency of Canada, is delivered in a single 1 mL dose and has been delivered to >200,000 people in an ongoing 2018–2020 outbreak of disease. To view this Bench to Bedside, open or download the PDF.
Source: CellCategories: General Medicine Journals and SocietiesTweet
-
Mashup Score: 1Reducing Treatment Burden in AMD - 4 year(s) ago
VEGF-A antagonists have revolutionized wet AMD treatment. Several challenges remain including high treatment burden requiring repeated intraocular injections for persistent disease. Brolucizumab directly inhibits VEGF-A function, providing visual outcomes comparable to aflibercept (an FDA-approved VEGF-A antagonist). Anatomic retinal outcomes including retinal fluid, a marker of disease activity,…
Source: CellCategories: General Medicine Journals and SocietiesTweet
Congrats to my @MSKCancerCenter colleagues Doris Ponce & @AlanHanash on leading great #benchtobedside study. Phase 2 study of Interleukin-22 and systemic corticosteroids as initial treatment for acute #GVHD of the lower GI tract @BloodJournal #bmtsm https://t.co/3nrSH22BwL